Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Financing Activities (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Cash from Financing Activities data on record, last reported at $19.2 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 9560.1% year-over-year to $19.2 million; the TTM value through Sep 2025 reached $62.9 million, up 192.04%, while the annual FY2024 figure was $28.4 million, 94.52% up from the prior year.
  • Cash from Financing Activities reached $19.2 million in Q3 2025 per SGMO's latest filing, down from $28.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $43.8 million in Q3 2022 and bottomed at -$1.6 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $11.4 million, with a median of $8.0 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: plummeted 110.29% in 2022, then skyrocketed 9560.1% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $2.1 million in 2021, then surged by 824.95% to $19.5 million in 2022, then tumbled by 99.15% to $167000.0 in 2023, then skyrocketed by 4086.23% to $7.0 million in 2024, then surged by 174.7% to $19.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $19.2 million in Q3 2025, $28.6 million in Q2 2025, and $8.1 million in Q1 2025.